Apogee Therapeutics, Inc. (APGE)

APGE · Biological Products, (No Diagnostic Substances) · Waltham, MA · filing with the SEC since 2023

Full chart Alerts Compare

Grade4.4

◀ Past 3.7● Present 5.3▶ Future 4.1

8 est.

Overview Business Financials Grade Forecast Sentiment Ownership People Filings Patents Chart

Filings

156 filings since 2017 beside 162 insider forms · Large accelerated filer · read from EDGAR on Nov 13, 2026

Due nextLarge accelerated filer

10-K Annual report for the fiscal year ending Dec 31, 2026Large accelerated filers have 60 days after the fiscal year ends. by Mar 1, 2027

A deadline is the latest date the SEC's rules allow for its filer category. It is not a forecast of the day the company files. Last time, the results release (8-K item 2.02) came 41 days after the quarter ended. The proxy statement was last filed Apr 24, 2026.

Filings a yearinsider forms included

538472109

2023202420252026

2026 counts to Nov 13, 2026.

Listing warning from its exchange (8-K item 3.01): 1 time in the last 36 months, the newest Sep 3, 2026.Officer or director change (8-K item 5.02): 4 times in the last 36 months, the newest Sep 3, 2026.SEC letters: 3 in the last 36 months, the newest Mar 5, 2024.

Insider forms 162

Insider forms (3, 4, 5 and 144) are counted each year but not listed here; the people and their trades are on the Ownership tab.

FiledFormWhat it is, in plain wordsPeriodAsk

Sep 14, 2026 15-12G Deregistration notice

Sep 8, 2026 SCHEDULE 13D/A Activist holder update, amended

Sep 3, 2026 25-NSE Delisting notice from the exchange

Sep 3, 2026 POSASR Automatic shelf amended

Sep 3, 2026 S-8 POS Employee stock plan update

Sep 3, 2026 8-K items 1.02, 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 9.01 Major agreement ended; Purchase or sale of a business completed; Listing warning from its exchange; Change to shareholders' rights; Change of control; Officer or director change; Charter, bylaw or fiscal-year change · Current report

Sep 3, 2026 SCHEDULE 13D/A Activist holder update, amended

Aug 11, 2026 8-K items 5.02, 5.07 Officer or director change; Shareholder vote · Current report

Aug 10, 2026 10-Q Quarterly report Jun 30, 2026

Aug 10, 2026 8-K items 2.02, 9.01 Results released · Current report

Aug 6, 2026 DEFA14A Extra proxy material

Aug 3, 2026 DEFA14A Extra proxy material

Jul 13, 2026 DEFM14A Merger proxy statement

Jul 8, 2026 SCHEDULE 13G/A Large holder update, amended

Jul 2, 2026 PREM14A Preliminary merger proxy

Jun 26, 2026 DEFA14A Extra proxy material

Jun 23, 2026 SCHEDULE 13D/A Activist holder update, amended

Jun 22, 2026 DEFA14A Extra proxy material

Jun 22, 2026 8-K items 1.01, 5.07, 7.01, 8.01, 9.01 Major agreement signed; Shareholder vote; Investor disclosure (Regulation FD); Other event · Current report Jun 18, 2026

Jun 22, 2026 8-K items 1.01, 9.01 Major agreement signed · Current report Jun 17, 2026

Jun 12, 2026 8-K item 5.07 Shareholder vote · Current report Jun 9, 2026

May 27, 2026 8-K items 1.01, 7.01, 9.01 Major agreement signed; Investor disclosure (Regulation FD) · Current report May 26, 2026

May 27, 2026 8-K items 7.01, 8.01, 9.01 Investor disclosure (Regulation FD); Other event · Current report

May 11, 2026 10-Q Quarterly report Mar 31, 2026

May 11, 2026 8-K items 2.02, 9.01 Results released · Current report

Apr 24, 2026 DEFA14A Extra proxy material

Apr 24, 2026 ARS Annual report to shareholders Dec 31, 2025

Apr 24, 2026 DEF 14A Proxy statement Jun 9, 2026

Apr 24, 2026 8-K item 5.02 Officer or director change · Current report Apr 21, 2026

Apr 8, 2026 SCHEDULE 13G/A Large holder update, amended

Mar 27, 2026 SCHEDULE 13D/A Activist holder update, amended

Mar 26, 2026 SCHEDULE 13G/A Large holder update, amended

Mar 25, 2026 8-K items 1.01, 9.01 Major agreement signed · Current report Mar 24, 2026

40 of 156 shown

Every row opens the filing on EDGAR. The plain words are the site's own for each form and each 8-K item; the complete history, insider forms included, is on EDGAR.

SI Assistanton APGE · research, not advice